Piper Sandler Downgrades Antares Pharma (ATRS) to Neutral

Piper Sandler analyst David Amsellem downgraded Antares Pharma (NASDAQ: ATRS) from Overweight to Neutral with a price target of $5.60 (from $6.00).

For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.

Shares of Antares Pharma closed at $5.58 yesterday.

You May Also Be Interested In

• Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
• Cellebrite (CLBT) PT Lowered to $15 at TD Cowen
• Adyen NV (ADYEN:NA) (ADYYF) PT Raised to EUR1,200 at Susquehanna